PARIS--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729), a medical technology company specializing in vertebral and knee-surgery implants, today announces the Board of Directors’ decision to appoint Mr Brian T. Ennis as a new Director.
Brian Ennis will bring to Implanet over 30 years of successful experience in the development and growth of medical technology companies. After 11 years at Stryker Corporation, where he held various marketing and vice president / general management positions in both Europe and the United States, he was President, International at Wright Medical Group, a group specializing in orthopedic devices and biotechnologies; President at Empi, a company specializing in electrotherapeutic medical solutions; and President and CEO at Etex Corporation for 6.5 years, successfully steering the transformation of this late stage startup specializing in the Research & Development of biomaterials into a profitable and viable high-growth company.
Brian Thomas Ennis states: “I am delighted to be joining Implanet’s Board of Directors. I have had the pleasure of following Implanet since its inception in 2007 and throughout its subsequent development. The executive management team has admirably built a solid foundation for growth, skillfully implemented a market penetration strategy for the United States, deftly maneuvered through the regulatory clearance process and aptly demonstrated the innovative JAZZ technology platform’s clinical merits. I look forward to assisting the management team in securing respected key opinion leaders in the spine market segment, rapidly expanding the US distribution channel, and promoting both the economic value and clinical benefits of this innovative technology.”
“We are delighted with Brian T. Ennis’ arrival as a Director. He has substantial and highly-successful experience in the development of divisions or companies in our sector of activity. He will be an additional asset to accompany Implanet’s international growth”, concludes Ludovic Lastennet, CEO of Implanet.
Next financial press release: Q1 2014 revenue, on 28 April 2014
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET’s proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 35 staff and recorded 2013 sales of €6.7 million.
For further information, please visit www.implanet.com